Hormonal

Adipose tissue insulin resistance (Adipo-IR) is a primary driver of metabolic and histological abnormalities in obese patients with NAFLD, with worsening Adipo-IR correlating with increased liver fibrosis and hepatic insulin resistance.

For obese individuals with fatty liver, simply having a high BMI is not the only risk factor; the metabolic health of the fat tissue matters significantly. If your fat tissue is insulin resistant, it releases fatty acids that damage the liver. Interventions that improve adipose tissue insulin sensitivity (like weight loss or specific medications like thiazolidinediones) may help reduce liver fibrosis and metabolic risk.